Achieve Life Sciences Adds Verona Pharma Alumni to Leadership Ahead of Key FDA Decision
Event summary
- Achieve Life Sciences appointed three senior leaders from Verona Pharma: Christopher Martin to the Board, Mark Zappia as SVP of Commercial, and Jim Willis as VP of Sales.
- The trio previously led the U.S. launch of Verona Pharma's Ohtuvayre, which was acquired by Merck for $10.8 billion in October 2025.
- Achieve recently secured up to $354 million in financing, including $180 million upfront, tied to FDA approval of cytisinicline.
- Tom King will step down from the Board in June 2026, with Dr. Lucian Iancovici assuming the role of Chairman.
The big picture
Achieve Life Sciences is fortifying its leadership team ahead of a critical FDA decision on cytisinicline, its lead candidate for smoking and vaping cessation. The appointments of Verona Pharma veterans signal a strategic push toward commercialization, following a $354 million financing round. The move comes as the company targets a market with significant unmet needs, including 25 million adult smokers and 18 million e-cigarette users in the U.S.
What we're watching
- Regulatory Milestone
- The pace at which Achieve secures FDA approval for cytisinicline by the June 20, 2026 PDUFA date will determine the timing of its commercial launch.
- Commercial Execution
- Whether the newly appointed leadership can replicate their success from Verona Pharma's Ohtuvayre launch in positioning cytisinicline in the smoking cessation market.
- Market Differentiation
- How Achieve will position cytisinicline as a first-of-its-kind treatment for vaping cessation, given the lack of FDA-approved alternatives.
Related topics